Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool January 18, 2011 Brian Orelli	Up 30%, Succeed Indeed! An aptly named clinical trial bodes well for Ariad Pharmaceuticals.
The Motley Fool November 3, 2011 Sean Williams	Bash My Stock: Ariad Pharmaceuticals For those of you who've wondered what's wrong with your stock...
The Motley Fool September 27, 2010 Brian Orelli	Better Buy: Ariad Pharmaceuticals or Corcept Therapeutics? A battle of drugless companies looking for their first hit.
The Motley Fool December 8, 2010 Brian Orelli	Winners and Losers at the Hematology Society Meeting The American Society of Hematology annual meeting wrapped up yesterday, and as with pretty much every medical meeting, we've got some winning and losing blood-cancer drugs.
The Motley Fool March 29, 2011 Brian Orelli	Partnership Now, Payoff Later ARIAD signs up a partner to develop a companion diagnostic.
The Motley Fool December 31, 2011 Brian Orelli	3 More Stock-Moving Binary Events to Watch in 2012 There are a lot of drugs that will face binary events in 2012 -- here are three to watch.
The Motley Fool May 6, 2010 Brian Orelli	Good Deal Now, Bad Deal Later: It's a Biotech Thing Ariad grabs cash now, but gives up long-term sales profits.
The Motley Fool August 2, 2007 Andrew R. Vaino	Ariad Gets Overlooked Ariad Pharmaceuticals has signed a deal with Merck to develop its sarcoma fighting drug. Ariad receives $75 million in cash for R&D, and validation of the drug's worth, but not the attention of investors.
The Motley Fool May 18, 2011 Brian Orelli	5 Biotech ASCO Abstracts to Watch The biotech investors' Christmas in May is once again upon us, where investors and researchers alike will be able to find the synopsis of what will be presented at the American Society of Clinical Oncology annual meeting next month.
The Motley Fool December 9, 2009 Brian Orelli	Rising From the ASHes At the Super Bowl of blood cancer, the American Society of Hematology's annual conference, the presentations by drug companies made a few stocks catch on fire, while a couple burned up a little.
The Motley Fool June 21, 2011 Alexander Crawford	Bullish Biotech: 5 Biotech Firms Making Great Strides These five biotech firms have just received great news. Should they be on your watch list?
The Motley Fool December 29, 2011 Brian Orelli	What to Look For With Seattle Genetics in 2012 The launch of its new drug Adcetris will be key.
The Motley Fool June 18, 2010 Brian Orelli	Double the Approvals! Double the Fun! These twins will take it. sanofi-aventis and Novartis both received FDA approvals for their cancer drugs yesterday.
Chemistry World June 12, 2012 Nina Notman	More testing needed for ridaforolimus US pharma company Merck & Co has confirmed that marketing approval for its anti-cancer drug ridaforolimus has been held up by the US Food and Drug Administration.
The Motley Fool February 16, 2010 Brian Orelli	For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward.
The Motley Fool March 22, 2005 Charly Travers	Do Good Drugs Guarantee Investment Success? By the time you know a drug is good, are you late to the party? Instead of trying to catch a train that has already zipped by, try investing in drug programs well in advance of phase 3 trials.
The Motley Fool December 12, 2011 Brian Orelli	FDA Irony: Less Data, Longer Review Poor Onyx Pharma.
The Motley Fool August 15, 2011 Jim Royal	6 Wild Bets on Biotech Riches The most interesting biotech tickers.
The Motley Fool August 22, 2011 Brian Orelli	Speedy in Seattle Seattle Genetics gets an early approval of Adcentris.
The Motley Fool June 9, 2010 Brian Orelli	ASCO Pops and Drops Themes and company news from the annual meeting of the American Society of Clinical Oncology.
BusinessWeek February 12, 2007 Gene G. Marcial	How Access Helps Treat Cancer Access pharmaceuticals is a tiny biotech trading over the counter. But its two cancer drugs are catching the eye of investors.
The Motley Fool June 7, 2010 Brian Orelli	Bristol Investors Go Crazy Wild. Are They Justified? Bristol-Myers Squibb is up a lot on an upgrade and some positive data coming out of the American Society of Clinical Oncology meeting, but investors need to be careful.
BusinessWeek May 28, 2009 Catherine Arnst	Make-or-Break Time for Cancer Drugs Strong presentations at the key oncology conference in late May will be crucial for struggling biotechs.
The Motley Fool September 8, 2010 Jim Mueller	3 Stocks to Play Biotech Three promising ideas for investing in this exciting area.
The Motley Fool April 28, 2009 Brian Orelli	Headline? Bad! Unexpected? No! For a company that only has one drug on the market, stopping a failing phase 3 clinical trial that's designed to expand the market of that drug is usually a major blow. But Onyx Pharmaceuticals was able to shrug it off.
The Motley Fool November 2, 2004 Charly Travers	Biotech's 5-Baggers: Part 3 Year after year, the hottest biotech companies with investors are those with drugs in development for the treatment of cancer.
The Motley Fool May 27, 2009 Brian Orelli	It's Approved! Now Back to Work Now that Bristol-Myers has received approval on its cancer drug Sprycel, it can get back to working on getting it out of its niche market and approved to treat other types of cancer.
The Motley Fool October 1, 2008 Brian Orelli	3 Drugmakers With Multiple Shots on Goal Well-stocked pipelines could kick these drugmakers into super-high gear.
The Motley Fool July 26, 2010 Brian Orelli	Up 20%! Guess That Hedge Wasn't Needed Onyx reports positive data for its recently acquired multiple myeloma drug.
The Motley Fool June 22, 2004 Charly Travers	Merck Pays Up for a Cancer Drug As demonstrated this morning with the announcement of a major deal with Vertex Pharmaceuticals, Merck is now in the midst of a strategic push to build out its oncology pipeline.
The Motley Fool August 27, 2007 Brian Orelli	Onyx: Old News Is Good News Onyx set a 52-week high today, even though the good news wasn't all that new. After the recent dearth of FDA approvals, investors may be flocking to a drug that's nearly certain to get the agency's thumbs-up.
The Motley Fool August 9, 2010 Jim Mueller	3 Stocks to Play Biotech Three promising ideas for investing in this exciting area.
The Motley Fool October 9, 2006 Brian Lawler	The Commandments of Biotech Investing, Part 2 It's a complex field, but it's not impossible for investors to master. The more in-depth your research of a potential biotech investment, and the more you remember to follow these commandments, the better your potential for success will be when investing in this fascinating field.
The Motley Fool June 2, 2009 Brian Orelli	ASCO's Big Winner Despite the massive changes in value that some small-cap biotech companies have seen before and during this year's American Society of Clinical Oncology annual meeting, the big winner from the confab is actually large pharmaceutical companies.
The Motley Fool October 26, 2010 Travis Hoium	ARIAD Pharmaceuticals Shares Plunged: What You Need to Know A day after shares pop, the company announced a stock offering at $3.70 per share, and shares drop.
The Motley Fool September 24, 2008 Brian Orelli	Ariad's Lawsuit Loss and Investors' Gamble Ariad Pharmaceuticals announces that it is on the losing end of its lawsuit.
The Motley Fool October 8, 2010 Luke Timmerman	Onyx Delays Cancer Drug Application As FDA Asks for More Data Shares fell about 7% in after-hours trading Thursday evening.
The Motley Fool March 26, 2007 Rich Duprey	Acquisitions Mark Pharmaceutical Industry Japan's Eisai's newest acquisition continues the trend of pharmaceuticals buying up biotechs. Investors, take note.
The Motley Fool January 26, 2005 Stephen D. Simpson	The Pipeline to Biotech Success Looking at drug R&D is the best way to begin assessing biotech companies as possible investment opportunities.
The Motley Fool August 28, 2006 Brian Lawler	The Commandments of Biotech Investing Since long-term successful biotech investing requires accurate risk assessment, you must be aware of the risk you're taking on. Just as with any prospective investment, if you diversify your biotech holdings, you can somewhat mitigate these various risks.
The Motley Fool March 3, 2009 Brian Orelli	Stop Worrying About Follow-On Biologics They're inevitable, but they won't hurt biotech as much as you might think.
Pharmaceutical Executive July 1, 2011	Precious Mettle Taking Onyx Pharmaceuticals to new heights: CEO Tony Coles talks about the midsize company's transition from adolescence to adulthood.
BusinessWeek June 16, 2011 Langreth & Cortez	When Two Cancer Drugs Are Better Than One Drugmakers are collaborating to test combinations of genetically targeted cancer drugs in hopes of boosting survival rates.
The Motley Fool October 31, 2006 Brian Lawler	A Look Inside the Biotech Haunted House Even after being warned of the risks, if you're still brave enough to come inside the biotech haunted house, realize that there are surprises. For example, the FDA will spook investors with calls for more clinical trials on drugs that appear to be a lock for approval.
The Motley Fool December 31, 2007 Brian Lawler	The Anatomy Of An Approved Drug An independent audit by the FDA provides a useful summary of the characteristics of drugs approved by the agency.
The Motley Fool June 15, 2011 Selena Maranjian	Make Money in Biotech the Easy Way There's no need to guess which biotech company will perform best with the SPDR S&P Biotech ETF.
The Motley Fool October 12, 2009 Brian Orelli	Onyx Strikes Gold A nice pipeline pickup for this pharmaceutical company.
The Motley Fool July 15, 2011 Brian Orelli	Seattle Genetics Will Work It Out This isn't the NFL labor negotiations.
Investment Advisor December 2005 Greg B. Scott	Buying The Future Prudent investing in biotechnology can offer great returns for clients. It's also the wave of the future. Armed with a basic understanding of the dynamics of the industry and the valuation inflection points, intelligent investors can make significant returns.
BusinessWeek June 13, 2005 Catherine Arnst	Biotech, Finally The past 30 years of biological discoveries, insights into the human genome, and exotic chemical manipulation have unleashed a wave of biological drugs, many of them reengineered human proteins.